Publications by authors named "Zhi-Fan Li"
Remnant Cholesterol and Residual Risk of Atherosclerotic Cardiovascular Disease.
Rev Cardiovasc Med
February 2025
Remnant cholesterol (RC) is increasingly recognized as a key target in the treatment of atherosclerotic cardiovascular disease (ASCVD), addressing much of the residual risk that persists despite standard therapies. However, integrating RC into clinical practice remains challenging. Key issues, such as the development of accessible RC measurement methods, the identification of safe and effective medications, the determination of optimal target levels, and the creation of RC-based risk stratification strategies, require further investigation.
View Article and Find Full Text PDFArticle Synopsis
- * Data from 31 patients show that this technique successfully guided punctures and accurately displayed intracranial targets, confirming effectiveness through postoperative imaging and results.
- * The findings suggest that this method is safe, simple to use, and beneficial for precise diagnosis and treatment in neurosurgery, indicating its potential for wider application.
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups.
Expert Opin Biol Ther
March 2024
Article Synopsis
- Dyslipidemia plays a key role in atherosclerotic cardiovascular disease (ASCVD), with patients who have lipid-rich vulnerable plaques being at higher risk for complications, despite existing lipid-lowering therapies (LLTs).
- The article reviews the effectiveness of monoclonal antibody (mAb) therapies, specifically those targeting PCSK9, in managing dyslipidemia and stabilizing vulnerable plaques, alongside a brief mention of mAbs targeting other proteins like ANGPTL3.
- Expert opinions highlight that mAb treatments not only improve lipid levels but also offer additional benefits like anti-inflammatory properties and support for vascular health, making them a promising alternative for managing dyslipidemia and preventing cardiovascular events.
Rationale and design of a randomized controlled trial: The effect of intensive lipid-lowering therapy with PCSK9 inhibitor on endothelial-coverage of stent strut after percutaneous coronary intervention (PCI) for patients with acute coronary syndrome (ACS): Optical coherence tomography (OCT) study (PIECES-OCT study).
Heliyon
November 2023
Article Synopsis
- Patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) typically need dual antiplatelet therapy for at least 1 year to reduce the risk of stent thrombosis, which is worsened by uncovered stent struts.
- This study investigates whether early use of a specific cholesterol-lowering treatment (PCSK9 monoclonal antibody) can improve the coverage of stent struts in ACS patients, compared to standard treatment, over 12 weeks.
- The research aims to provide insights that could lead to changes in treatment strategies for ACS patients, particularly the potential combination of intensive lipid-lowering therapy and shortened duration of antiplatelet therapy.
Article Synopsis
- - The study aimed to evaluate how effective sacubitril/valsartan is in lowering blood pressure in diabetes patients with primary hypertension, as well as its impact on glycolipid metabolism compared to olmesartan.
- - In the trial with 124 participants, patients taking sacubitril/valsartan experienced a significantly greater reduction in systolic blood pressure and had a higher percentage meeting their blood pressure target compared to those on olmesartan.
- - While both medications led to improvements in glucose and lipid levels, sacubitril/valsartan did not show any adverse effects and proved to be more effective in achieving blood pressure goals.
Postprocedural cardiac troponin I (cTnI) elevation commonly occurs in patients undergoing percutaneous coronary intervention (PCI); however, its prognostic value remains controversial. This study aimed to investigate the prognostic value of peak postprocedural cTnI in cardiac patients with or without three-vessel disease (TVD) undergoing complete PCI. A total of 1237 consecutive patients (77% males, mean age 58 ± 10 years) with normal baseline cTnI levels were enrolled, 439 patients (77% males, 59 ± 10 years) with TVD, and 798 patients (77% males, 57 ± 10 years) with single- or double-vessel disease (non-TVD).
View Article and Find Full Text PDFRefractory hypercholesterolemia (RH), including homozygous familial hypercholesterolemia (HoFH) and compound heterozygous familial hypercholesterolemia, is characterized by high levels of low-density lipoprotein cholesterol (LDL-C) despite existing cholesterol-lowering methods at maximal tolerable doses. Patients with RH have early onset and higher risk of atherosclerotic cardiovascular disease (ASCVD) under insufficient treatment. Therefore, it is urgent to seek new therapies to maintain the blood lipids in refractory hyperlipidemia at normal levels.
View Article and Find Full Text PDFAim: The aim of this study was to evaluate the relationship between renal function and low-density lipoprotein cholesterol (LDL-C) goal achievement and compare the strategy of lipid-lowering therapy (LLT) among the patients with coronary artery disease (CAD) with different renal functions.
Methods: In this study, we enrolled 933 Chinese patients with CAD from September 2020 to June 2021 admitted to the Cardiometabolic Center of Fuwai Hospital in Beijing consecutively. All individuals were divided into two groups based on their estimated glomerular filtration rate (eGFR).
The aim of our study is to evaluate the association of rotational atherectomy (RA) operation procedural indices and baseline lipid parameters with the prognosis of the patients with severe coronary calcification who underwent RA. Our study population consists of 287 patients treated with RA in Fuwai Hospital from January 2013 to December 2019. We analyzed the patients' rotation procedural indices including the number of burrs, the size of burrs, approach site, the size of guiding catheter, along with the baseline level of lipoprotein(a) (Lp(a)), low-density lipoprotein-cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP) to examine the association of these measurements with the prognosis of these patients using Cox regression analysis and Kaplan-Meier survival analysis.
View Article and Find Full Text PDFRationale: Presence of synchronous double hepatocelluar carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) (sdpHCC-ICC) located separately within a single liver is extremely rare. The purpose of this study is to investigate the clinical, imaging, pathological characteristics, and prognosis of patients with sdpHCC-ICC, in order to enhance our understanding of the disease and improve diagnostic and therapeutic effect.
Patient Concerns: A 49-year-old, female with the diagnosis of hepatitis B virus with obvious liver cirrhosis, was admitted to our hospital.
Background: Accurate and early diagnosis of residual tumors or intrahepatic recurrences after TACE is critically needed for determining the success of treatments and for guiding subsequent therapeutic planning. This meta-analysis was performed to assess the efficacy of diffusion weighted imaging (DWI) with the quantitative apparent diffusion coefficient (ADC) value in diagnosing residual or recurrent hepatocellular carcinoma after transarterial chemoembolization (TACE).
Materials And Methods: A comprehensive literature search of PubMed, Embase, Web of Science, Scopus and the Cochrane Library database, from inception to July 2019, was conducted to select original studies on diagnosing residual or recurrent HCCs after TACE using DWI sequence with its ADC value.